LONSURF (Trifluridine & Tipiracil) 15 mg/6.14mg / 20 mg/8.19mg Tablets

Concepts

• antrim
• tablets
• tipiracil
• trifluridine
• lonsurf
• lonsurf (trifluridine & tipiracil
• a period
• up to 3 years
• years
• and

Location

Description

Contract for supply of LONSURF (Trifluridine & Tipiracil) 15 mg/6.14mg and 20 mg/8.19mg Tablets for a period of up to 3 years

Award Detail

CPV Codes

• None found

Legal Justification

Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists. Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract - (a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods,services or works. The Northern Health and Social Care Trust requires the purchase of Lonsurf tablets which is subject to patent protection / Sole MA Holder and consequently no reasonable alternative of substitute exists. The absence of competition is not the artificial narrowing of the parameters of the procurement.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **